Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

89Bio Inc (ETNB)

89Bio Inc (ETNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 842,640
  • Shares Outstanding, K 106,126
  • Annual Sales, $ 0 K
  • Annual Income, $ -142,190 K
  • EBIT $ -304 M
  • EBITDA $ -309 M
  • 60-Month Beta 1.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.83

Options Overview Details

View History
  • Implied Volatility 113.18% ( +13.05%)
  • Historical Volatility 75.88%
  • IV Percentile 96%
  • IV Rank 74.78%
  • IV High 141.91% on 10/01/24
  • IV Low 28.02% on 08/20/24
  • Put/Call Vol Ratio 0.29
  • Today's Volume 22
  • Volume Avg (30-Day) 130
  • Put/Call OI Ratio 1.63
  • Today's Open Interest 19,082
  • Open Int (30-Day) 18,891

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.79
  • Number of Estimates 5
  • High Estimate -0.56
  • Low Estimate -1.03
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -58.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.43 +23.48%
on 12/19/24
9.71 -18.23%
on 12/02/24
-0.04 (-0.50%)
since 11/20/24
3-Month
6.43 +23.48%
on 12/19/24
10.72 -25.93%
on 11/11/24
-0.25 (-3.05%)
since 09/20/24
52-Week
6.43 +23.48%
on 12/19/24
16.63 -52.25%
on 03/04/24
-2.29 (-22.39%)
since 12/20/23

Most Recent Stories

More News
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB : 7.94 (+12.94%)
New Strong Sell Stocks for November 16th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:ClevelandCliffs CLF is the largest producer of iron ore pellets in North America. The Zacks Consensus Estimate for its current...

ETNB : 7.94 (+12.94%)
CLF : 9.38 (+0.54%)
HZO : 28.35 (-1.63%)
Insider Purchase: Chief Executive Officer of $ETNB (ETNB) Buys 5,000 Shares

ROHAN PALEKAR, the Chief Executive Officer of $ETNB ($ETNB), bought 5,000 shares of the company on 12-06-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

ETNB : 7.94 (+12.94%)
Insider Purchase: Director at $ETNB (ETNB) Buys 10,000 Shares

Charles McWherter, a director at $ETNB ($ETNB), bought 10,000 shares of the company on 12-05-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

ETNB : 7.94 (+12.94%)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB : 7.94 (+12.94%)
89bio to Participate in the 7th Annual Evercore HealthCONx Conference

ETNB : 7.94 (+12.94%)
Insider Purchase: Chief Executive Officer of $ETNB (ETNB) Buys 10,000 Shares

ROHAN PALEKAR, the Chief Executive Officer of $ETNB ($ETNB), bought 10,000 shares of the company on 11-22-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This...

ETNB : 7.94 (+12.94%)
89bio, Inc. Presents New Data from Phase 2b ENLIVEN Trial of Pegozafermin for Advanced MASH at AASLD 2024

89bio presented new Phase 2b trial data on pegozafermin for treating advanced MASH, highlighting potential benefits in fibrosis reversal.Quiver AI Summary89bio, Inc. announced new analyses from its Phase...

ETNB : 7.94 (+12.94%)
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

ETNB : 7.94 (+12.94%)
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

ETNB : 7.94 (+12.94%)

Business Summary

89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis....

See More

Key Turning Points

3rd Resistance Point 9.74
2nd Resistance Point 8.85
1st Resistance Point 8.39
Last Price 7.94
1st Support Level 7.04
2nd Support Level 6.15
3rd Support Level 5.69

See More

52-Week High 16.63
Fibonacci 61.8% 12.73
Fibonacci 50% 11.53
Fibonacci 38.2% 10.33
Last Price 7.94
52-Week Low 6.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar